Literature DB >> 25090946

Therapy: oral or subcutaneous methotrexate for rheumatoid arthritis?

Sabri Alsaeedi1, Edward C Keystone2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25090946     DOI： 10.1038/nrrheum.2014.129

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

Review 1.  2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Authors:  Jasvinder A Singh; Daniel E Furst; Aseem Bharat; Jeffrey R Curtis; Arthur F Kavanaugh; Joel M Kremer; Larry W Moreland; James O'Dell; Kevin L Winthrop; Timothy Beukelman; S Louis Bridges; W Winn Chatham; Harold E Paulus; Maria Suarez-Almazor; Claire Bombardier; Maxime Dougados; Dinesh Khanna; Charles M King; Amye L Leong; Eric L Matteson; John T Schousboe; Eileen Moynihan; Karen S Kolba; Archana Jain; Elizabeth R Volkmann; Harsh Agrawal; Sangmee Bae; Amy S Mudano; Nivedita M Patkar; Kenneth G Saag
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

2.  Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.

Authors:  Ray Fitzpatrick; David Gi Scott; Ian Keary
Journal:  Clin Rheumatol       Date:  2013-07-09       Impact factor: 2.980

3.  Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study.

Authors:  M F Bakker; J W G Jacobs; P M J Welsing; J H van der Werf; S P Linn-Rasker; M J van der Veen; F P J G Lafeber; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2010-05-28       Impact factor: 19.103

4.  Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.

Authors:  Monique Hoekstra; Cees Haagsma; Cees Neef; Johannes Proost; Antonius Knuif; Mart van de Laar
Journal:  J Rheumatol       Date:  2004-04       Impact factor: 4.666

5.  Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.

Authors:  J Braun; P Kästner; P Flaxenberg; J Währisch; P Hanke; W Demary; U von Hinüber; K Rockwitz; W Heitz; U Pichlmeier; C Guimbal-Schmolck; A Brandt
Journal:  Arthritis Rheum       Date:  2008-01

6.  Use of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United States.

Authors:  Jeffrey R Curtis; Jie Zhang; Fenglong Xie; Tim Beukelman; Lang Chen; Joaquim Fernandes; Seth Ginsberg; Claire Spettell; Huifeng Yun; Kenneth G Saag; Michael Schiff
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-11       Impact factor: 4.794

7.  Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.

Authors:  K Visser; W Katchamart; E Loza; J A Martinez-Lopez; C Salliot; J Trudeau; C Bombardier; L Carmona; D van der Heijde; J W J Bijlsma; D T Boumpas; H Canhao; C J Edwards; V Hamuryudan; T K Kvien; B F Leeb; E M Martín-Mola; H Mielants; U Müller-Ladner; G Murphy; M Østergaard; I A Pereira; C Ramos-Remus; G Valentini; J Zochling; M Dougados
Journal:  Ann Rheum Dis       Date:  2008-11-25       Impact factor: 19.103

8.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103

9.  Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration.

Authors:  Michael H Schiff; Jonathan S Jaffe; Bruce Freundlich
Journal:  Ann Rheum Dis       Date:  2014-04-12       Impact factor: 19.103
  9 in total
  2 in total

1.  Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal.

Authors:  Anand N Malaviya; S B Gogia
Journal:  Clin Rheumatol       Date:  2016-04-28       Impact factor: 2.980

Review 2.  [Recommendations when switching therapy from immunosuppressive drugs to dupilumab in patients with atopic dermatitis].

Authors:  Johannes Wohlrab; Ulrich Mrowietz; Stephan Weidinger; Thomas Werfel; Andreas Wollenberg
Journal:  Hautarzt       Date:  2021-04       Impact factor: 0.751
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.